Stayble Therapeutics AB (DE:4K4)
FRANKFURT:4K4
4K4 Stock Chart & Stats
€0.02
>-€0.01(-2.27%)
At close: 4:00 PM EST
€0.02
>-€0.01(-2.27%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.12M
Enterprise Value€9.78M
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Burn And Profitability TrendReported operating losses and cash outflows have materially narrowed into 2025, reflecting sustained cost control and program efficiency gains. A shrinking burn rate lengthens runway per financing round and reduces dilution pressure, improving the firm's ability to advance clinical programs without immediate funding.
Low Financial LeverageNear-zero reported debt provides balance-sheet flexibility critical for pre-revenue biotech firms. Low leverage limits interest obligations and reduces refinancing risk, enabling the company to prioritize R&D spending and negotiate funding from equity or strategic partners without immediate debt-service constraints.
Focused, Disease-modifying Clinical ProgramA single, clearly defined lead program targeting underlying disc pathology gives a focused R&D agenda and potential clinical differentiation versus symptomatic therapies. If successful, a disease-modifying approach could create a durable competitive advantage and clearer regulatory/partnering value propositions.
Bears Say
Pre-commercial Profile With No RevenueAbsent product revenues, the company must rely on external financing or partnerships to fund operations. This structural revenue gap increases execution risk: clinical setbacks or slower development timelines raise the probability of additional capital raises and dilution before self-sustaining cash generation.
Compressed Equity Base And Shrinking AssetsA materially reduced equity cushion and declining assets limit the company's ability to absorb further losses or pursue parallel programs. This compressed balance sheet raises funding urgency and heightens dilution risk if future capital is required, constraining strategic optionality.
Persistent Negative Operating Cash Flow And FCFSustained negative operating and free cash flow means the business is not yet self-funding; although burn is improving, the company remains exposed to financing cycles. Reliance on external capital creates execution and timing risk that can materially affect program timelines and ownership dilution.
4K4 FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is €1.12M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Stayble Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in DE:4K4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.